The Wayback Machine - https://web.archive.org/web/20090612083915/http://www.ohiomeansbusiness.com:80/key/bioscience.php
Top Border

Ohio's bioscience leadership stimulates knowledge transfer that
promotes innovation and allows quick and cost effective
solutions to scientific challenges

With more than $2.5 billion in funding and 1,141 bioscience entities in operation throughout the state, Ohio is establishing an international leadership role in the cutting-edge bioscience industry.

This complex field centers on research, development and marketing of pharmaceuticals, diagnostics, bioinformatics, medical devices, medical equipment and other health-related products. Bioscience companies represent not only the next wave for the global economy but also opportunity for dramatic advances in the human experience.

Primary Bioscience Sectors

Ohio's primary bioscience sectors apply technology and service to a variety of market needs:

  • Pharmaceuticals and diagnostics – Cleveland's Auburn Pharmaceuticals is developing a novel anti-cancer drug that strives to make radiation and chemotherapy treatment more effective.
  • Medical devices and equipment – Akron-based Theken Surgical is developing new spinal implant technology utilizing medical polymers and bionanotechnology.
  • Imaging – Cleveland's Imalux Corporation has brought to market its Niris Imaging System creating superior imaging to ultrasound utilizing harmless near-infrared light.
  • Contract research – At Columbus Children's Research Institute, a wholly owned subsidiary of Columbus Children's Hospital, study of gene therapy is developing novel technology for gene transfer targeting genetic defects, chronic illness and an HIV vaccine.
  • Agbio – Cincinnati-based Stolle Milk Biologics is a pioneer in the discovery and development of cow's milk with increased levels of selected antibodies and other factors that have led to advances in anti-inflammatory effects, cardiovascular health and immune system function.

State efforts to establish Ohio as a preferred destination for bioscience academia and industry resulted in an average of 66 new or relocated companies each year between 2004 and 2007. In 2007 alone, Ohio welcomed 60 bioscience organizations by way of new company launches or companies establishing their first facility in the state. Eight of those additions are companies that migrated to Ohio from other states or other countries—such as Israel, Japan, and Australia. Ohio's bioscience entities generate more than $148 billion in total economic impact and employ more than 1.4 million skilled workers.

Noteworthy 2007 expansions include: Philips Medical expanding R&D; space for their imaging systems in Highland Heights; growing CROs like Kendle International in Cincinnati, Charles River Labs in Spencerville, and WIL Research in Ashland; Ben Venue Labs' new 244,000 square foot facility; and Cardinal Health breaking ground on a $50 million, 250,000 square foot facility at its Dublin, Ohio, headquarters.

Ohio understands the critical importance of funding access for this innovative industry and has launched an unprecedented investment making available substantial grant funding. Overall, more than $2.5 billion were invested across Ohio to accelerate Ohio's bioscience growth in 2007, nearly doubling the 2006 total.

Between January 2002 and June 2008, over $400 million of Ohio's $1.6 billion Third Frontier funds had been competitively awarded to support bioscience-related development and commercialization initiatives. Since 2002 more than 90 diverse biomedical projects have been funded by Ohio's Third Frontier, epitomizing the breadth and depth of the state's bioscience-based economic development.

Red, Green and White

Based on the color model established by European bioscience leaders, Ohio's strength in the Red (health), Green (agriculture) and White (industrial) bioscience industry sectors stimulates innovation, promotes cross-collaboration and provides cost-effective solutions to scientific challenges.

Ohio's Red, Green and White bioscience entities generate more than $5.2 billion in direct economic impact and employ more than 37,000 skilled workers.

Clinical Network

Ohio's superior medical system helps explain the state's emerging dominance in the bioscience field. In U.S. News & World Report's 2008 "America's Best Hospitals" list, 14 Ohio hospitals were ranked among the nation's top 220 hospitals in a variety of specialties, ranking Ohio among the top 5 states. The 2008 U.S. News & World Report "America's Best Children's Hospitals" rankings show that 4 of the top 15 pediatric hospitals are in Ohio—Cincinnati Children's Hospital Medical Center (3rd ), University Hospital's Rainbow Babies & Children's Hospital in Cleveland (5th), Children's Hospital Cleveland Clinic (14th) and Nationwide Children's in Columbus (15th). Due in part to its strong clinical network and medical reputation, Ohio hosted 16 percent of all clinical trials conducted in the U.S.

To learn more about Ohio's bioscience industry, contact BioOhio at 1-614-675-3686.

bottom border